Go Pro

Michael G. King Jr. Analyst Performance

Analyst at Rodman & Renshaw

Michael G. King Jr. is a stock analyst at Rodman & Renshaw focused in the medical sector, covering 3 publicly traded companies. Over the past year, Michael G. King Jr. has issued 3 stock ratings, including and buy recommendations. While full access to Michael G. King Jr.'s proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Michael G. King Jr.'s coverage history, rating activity, and performance tendencies — helping individual investors make more informed trading decisions.

Analyst Rankings, Coverage, and Performance Statistics

Average Return
00.00% 12-Month ROI
Success Rate
00.00% Profitable Ratings
Total Ratings
3 Last 0 Years
Buy Recommendations
100.00% 3 Buy Ratings
Companies Covered
3 Unique Companies

Ratings Distribution

RatingPercentageCount
Strong Buy0.0%0 ratings
Buy100.0%3 ratings
Hold0.0%0 ratings
Sell0.0%0 ratings

the majority (100.0%) have been Buy recommendations.

Best & Worst Calls

This analyst does not have any ratings with enough history to determine best and worst calls.

Exchange Coverage

ExchangePercentageCount
NASDAQ
100.0% of companies on NASDAQ
3 companies

Michael G. King Jr., an analyst at Rodman & Renshaw, currently covers 3 companies listed on , with the majority traded on NASDAQ.

Coverage Focus

Sector IconSectorPercentage
Medical
2 companies
66.7%
Manufacturing
1 company
33.3%

Michael G. King Jr. of Rodman & Renshaw specializes in stock coverage within the Medical sector, with additional focus on Manufacturing companies.

Coverage Industries

IndustryPercentage
MED INSTRUMENTS
1 company
33.3%
PHARMACEUTICAL PREPARATIONS
1 company
33.3%
MED - BIOMED/GENE
1 company
33.3%

Michael G. King Jr.'s Ratings History at Rodman & Renshaw

Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.
Available with a MarketBeat All Access Subscription
12-Month ROIUpgrade to All Access to use the All ROI Filter
CompanyReport DateActionReport Date Price12-Month
Price Target
Rating12-Month
Price & ROI
Details
Atossa Genetics Inc. stock logo
ATOS
Atossa Genetics
7/7/2026Initiated Coverage$2.28$12.00Buy
Kyntra Bio Inc stock logo
KYNB
Kyntra Bio
6/9/2026Initiated Coverage$6.63$30.00Buy
Bolt Biotherapeutics, Inc. stock logo
BOLT
Bolt Biotherapeutics
5/28/2026Initiated Coverage$5.39$22.00Buy